Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
10 11 2020
Historique:
received: 01 07 2020
revised: 16 09 2020
accepted: 29 09 2020
pubmed: 20 10 2020
medline: 13 11 2020
entrez: 19 10 2020
Statut: ppublish

Résumé

More than 100 COVID-19 vaccine candidates are in development since the SARS-CoV-2 genetic sequence was published in January 2020. The uptake of a COVID-19 vaccine among children will be instrumental in limiting the spread of the disease as herd immunity may require vaccine coverage of up to 80% of the population. Prior history of pandemic vaccine coverage was as low as 40% among children in the United States during the 2009 H1N1 influenza pandemic. To investigate predictors associated with global caregivers' intent to vaccinate their children against COVID-19, when the vaccine becomes available. An international cross sectional survey of 1541 caregivers arriving with their children to 16 pediatric Emergency Departments (ED) across six countries from March 26 to May 31, 2020. 65% (n = 1005) of caregivers reported that they intend to vaccinate their child against COVID-19, once a vaccine is available. A univariate and subsequent multivariate analysis found that increased intended uptake was associated with children that were older, children with no chronic illness, when fathers completed the survey, children up-to-date on their vaccination schedule, recent history of vaccination against influenza, and caregivers concerned their child had COVID-19 at the time of survey completion in the ED. The most common reason reported by caregivers intending to vaccinate was to protect their child (62%), and the most common reason reported by caregivers refusing vaccination was the vaccine's novelty (52%). The majority of caregivers intend to vaccinate their children against COVID-19, though uptake will likely be associated with specific factors such as child and caregiver demographics and vaccination history. Public health strategies need to address barriers to uptake by providing evidence about an upcoming COVID-19 vaccine's safety and efficacy, highlighting the risks and consequences of infection in children, and educating caregivers on the role of vaccination.

Sections du résumé

BACKGROUND
More than 100 COVID-19 vaccine candidates are in development since the SARS-CoV-2 genetic sequence was published in January 2020. The uptake of a COVID-19 vaccine among children will be instrumental in limiting the spread of the disease as herd immunity may require vaccine coverage of up to 80% of the population. Prior history of pandemic vaccine coverage was as low as 40% among children in the United States during the 2009 H1N1 influenza pandemic.
PURPOSE
To investigate predictors associated with global caregivers' intent to vaccinate their children against COVID-19, when the vaccine becomes available.
METHOD
An international cross sectional survey of 1541 caregivers arriving with their children to 16 pediatric Emergency Departments (ED) across six countries from March 26 to May 31, 2020.
RESULTS
65% (n = 1005) of caregivers reported that they intend to vaccinate their child against COVID-19, once a vaccine is available. A univariate and subsequent multivariate analysis found that increased intended uptake was associated with children that were older, children with no chronic illness, when fathers completed the survey, children up-to-date on their vaccination schedule, recent history of vaccination against influenza, and caregivers concerned their child had COVID-19 at the time of survey completion in the ED. The most common reason reported by caregivers intending to vaccinate was to protect their child (62%), and the most common reason reported by caregivers refusing vaccination was the vaccine's novelty (52%).
CONCLUSIONS
The majority of caregivers intend to vaccinate their children against COVID-19, though uptake will likely be associated with specific factors such as child and caregiver demographics and vaccination history. Public health strategies need to address barriers to uptake by providing evidence about an upcoming COVID-19 vaccine's safety and efficacy, highlighting the risks and consequences of infection in children, and educating caregivers on the role of vaccination.

Identifiants

pubmed: 33071002
pii: S0264-410X(20)31317-7
doi: 10.1016/j.vaccine.2020.09.084
pmc: PMC7547568
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Viral Vaccines 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

7668-7673

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Vaccine. 2014 Nov 20;32(49):6649-54
pubmed: 25280436
Vaccine. 2011 Sep 2;29(38):6472-84
pubmed: 21756960
Int J Public Health. 2020 Jul;65(6):711-712
pubmed: 32529534
BMJ. 2009 Oct 27;339:b4164
pubmed: 19861377
Public Health Rep. 2005 May-Jun;120(3):252-8
pubmed: 16134564
Soc Sci Med. 2020 Nov;265:113414
pubmed: 33038683
Vaccine. 2013 Oct 1;31(42):4860-6
pubmed: 23954379
CMAJ. 2003 Jan 7;168(1):39-41
pubmed: 12515783
Pediatrics. 2011 Jul;128(1):79-85
pubmed: 21708796
J R Soc Interface. 2012 Sep 7;9(74):2234-43
pubmed: 22496100
BMC Public Health. 2010 Oct 10;10:596
pubmed: 20932342
JAMA. 2020 Jun 23;323(24):2458-2459
pubmed: 32421155
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
Eur J Public Health. 2010 Oct;20(5):490-4
pubmed: 20444821
Eur J Pediatr. 2011 Sep;170(9):1165-72
pubmed: 21347848
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
BMJ. 2020 Apr 27;369:m1679
pubmed: 32340998
PLoS One. 2010 Apr 16;5(4):e10199
pubmed: 20421908
Vaccine. 2011 Mar 16;29(13):2421-8
pubmed: 21277402
JAMA. 2020 Jul 21;324(3):294-296
pubmed: 32511676
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
PLoS One. 2014 Jul 24;9(7):e102505
pubmed: 25057914
J Dev Behav Pediatr. 2011 Sep;32(7):491-8
pubmed: 21516041
Arch Pediatr Adolesc Med. 2005 May;159(5):470-6
pubmed: 15867122

Auteurs

Ran D Goldman (RD)

The Pediatric Research in Emergency Therapeutics (PRETx) Program, Division of Emergency Medicine, Department of Pediatrics, University of British Columbia, and BC Children's Hospital Research Institute, Vancouver, BC, Canada. Electronic address: rgoldman@cw.bc.ca.

Tyler D Yan (TD)

The Pediatric Research in Emergency Therapeutics (PRETx) Program, Division of Emergency Medicine, Department of Pediatrics, University of British Columbia, and BC Children's Hospital Research Institute, Vancouver, BC, Canada.

Michelle Seiler (M)

Emergency Department, University Children's Hospital Zurich, Zurich, Switzerland.

Cristina Parra Cotanda (C)

Hospital Sant Joan de Déu Barcelona, Pediatric Emergency Department, Barcelona, Spain.

Julie C Brown (JC)

Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA, USA.

Eileen J Klein (EJ)

Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA, USA.

Julia Hoeffe (J)

Pediatric Emergency Medicine, Inselspital University Hospital of Bern, Bern, Switzerland.

Renana Gelernter (R)

Pediatric Emergency Medicine Unit, Assaf Harofeh Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel.

Jeanine E Hall (JE)

Division of Emergency and Transport Medicine, Children's Hospital Los Angeles, USC Keck School of Medicine, Los Angeles, CA, USA.

Adrienne L Davis (AL)

Pediatric Emergency Medicine, Hospital for Sick Children and University of Toronto, ON, Canada.

Mark A Griffiths (MA)

Division of Pediatric Emergency Medicine, Children's Healthcare of Atlanta, Emory School of Medicine, Atlanta, GA, USA.

Ahmed Mater (A)

Pediatric Emergency Medicine, Jim Pattison Children's Hospital, and University of Saskatchewan, Saskatoon, SK, Canada.

Sergio Manzano (S)

Department of Pediatric Emergency Medicine, Geneva Children's Hospital, Geneva University Hospitals, and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Gianluca Gualco (G)

Pediatric Emergency Department, Pediatric Institute of Italian part of Switzerland, Ticino, Switzerland.

Naoki Shimizu (N)

Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan.

Thomas L Hurt (TL)

Department of Emergency Medicine, Mary Bridge Children's Hospital, Tacoma, WA, USA.

Sara Ahmed (S)

Department of Emergency Medicine, Mary Bridge Children's Hospital, Tacoma, WA, USA.

Matt Hansen (M)

Emergency Medicine, Oregon Health and Science University, Doernbecher Children's Hospital, Portland, OR, USA.

David Sheridan (D)

Emergency Medicine, Oregon Health & Science University, Doernbecher Children's Hospital, Portland, OR, USA.

Samina Ali (S)

Departments of Pediatrics, Faculty of Medicine & Dentistry, Women and Children's Health Research Institute, University of Alberta, Edmonton, AB, Canada.

Graham C Thompson (GC)

Pediatrics and Emergency Medicine, Alberta Children's Hospital and University of Calgary, Calgary, AB, Canada.

Nathalie Gaucher (N)

Pediatric Emergency Medicine CHU Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada.

Georg Staubli (G)

Emergency Department, University Children's Hospital Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH